Mike Gladstone, global president and general manager of Pfizer Inflammation and Immunology unit, said that the acquisition of Arena is in line with the company’s capabilities and expertise in immunology and inflammatory-related conditions. Over the years, Pfizer has successfully created an innovation engine that develops potential medicines for patients worldwide with chronic and debilitating immuno-inflammatory conditions. The company understands that there is an urgent need to look into other treatment options with high potential, which is where Arena’s cannabinoid-drug pipeline comes in.
In 1970, Tom Forçade put a pie in a federal commissioner’s face. When the government…
Thailand is moving closer to putting its medical-only cannabis model into national law, with a…
President Trump signed Executive Order 14401, directing the FDA to fast-track review of psychedelic compounds…
Cannabis use among U.S. teens has declined substantially even as adult-use legalization has expanded, challenging…
An Australian company says its THC-free tablet could become the world’s first registered prescription CBD…
That's how many marijuana arrests American police reported between 1990 and 2025, according to FBI-derived…